Zobrazeno 1 - 10
of 73
pro vyhledávání: '"R. Brett McQueen"'
Autor:
Ivett Jakab, Melanie D. Whittington, Elizabeth Franklin, Susan Raiola, Jonathan D. Campbell, Zoltán Kaló, R. Brett McQueen
Publikováno v:
Frontiers in Pharmacology, Vol 12 (2021)
Background: Defining the value of healthcare is an elusive target, and depends heavily on the decision context and stakeholders involved. Cost-utility analysis and the quality-adjusted life year (QALY) have become the method and value definition of c
Externí odkaz:
https://doaj.org/article/893917d308bb45338a80136b69e6eedb
Publikováno v:
PharmacoEconomics. 41:321-327
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::812e5938bcd4ce145055a828ea348b5c
https://doi.org/10.1007/s40273-022-01230-x
https://doi.org/10.1007/s40273-022-01230-x
Autor:
R. Brett McQueen, Nicholas D. Mendola, Ivett Jakab, Jeffrey Bennett, Kavita V. Nair, Bertalan Németh, András Inotai, Zoltán Kaló
Publikováno v:
PharmacoEconomics - Open. 7:217-228
Several novel methods have been suggested to extend a conventional value assessment to capture a more comprehensive perspective of value from a patient perspective. The objective of this research was to demonstrate a framework for implementing a comb
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ec37948d11531c26b1d61868443b8199
https://doi.org/10.1007/s41669-022-00376-w
https://doi.org/10.1007/s41669-022-00376-w
Autor:
R. Brett McQueen, Seth J. Baum, Michael J. Louie, William J. Sasiela, Aikaterini Bilitou, Hemal Shah, Beth Nash, Kristin K. Gillard, Kausik K. Ray
Publikováno v:
American Journal of Cardiovascular Drugs. 23:67-76
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f9caf57c7702dd4bab5f5dc3c86457bb
https://doi.org/10.1007/s40256-022-00552-7
https://doi.org/10.1007/s40256-022-00552-7
Autor:
David M Rind, R. Brett McQueen, Serina Herron-Smith, Belén Herce-Hagiwara, Eric Gutierrez, Jon D Campbell, Noemi Fluetsch, Steven D Pearson
Publikováno v:
Journal of Managed Care & Specialty Pharmacy. 28:577-580
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2f79da5a0d89dd65b78e473fb841df17
https://doi.org/10.18553/jmcp.2022.28.5.577
https://doi.org/10.18553/jmcp.2022.28.5.577
Autor:
Ijeoma Edoka, Carleigh Krubiner, Andrew Mirelman, R. Brett McQueen, Mark Sculpher, Julia F. Slejko, Tommy Wilkinson
Publikováno v:
Handbook of Applied Health Economics in Vaccines ISBN: 0192896083
This chapter explains some of the important considerations for reporting and interpreting the results of economic evaluations. Once a model has been developed, and populated with parameter information, an investigator should be prepared to understand
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::189c20447e850397ef00dcdddc170705
https://doi.org/10.1093/oso/9780192896087.003.0018
https://doi.org/10.1093/oso/9780192896087.003.0018
Autor:
Andrea K, Steck, Fran, Dong, Cristy, Geno Rasmussen, Kimberly, Bautista, Flor, Sepulveda, Judith, Baxter, Liping, Yu, Brigitte I, Frohnert, Marian J, Rewers, Marian, Rewers, Aaron, Barbour, Daniel, Felipe-Morales, Paul, Dormond-Brooks, Kimberly, Driscoll, Brigitte, Frohnert, Cristy Geno, Rasmussen, Patricia, Gesualdo, Michelle, Hoffman, Rachel, Karban, Hanan, Shorrosh, Kimberly, Simmons, Andrea, Steck, Iman, Taki, Kathleen, Waugh, Edwin, Liu, Marisa, Gallant, R Brett, McQueen, Jill M, Norris
Publikováno v:
Diabetes Care. 45:365-371
OBJECTIVE Children identified with stage 1 type 1 diabetes are at high risk for progressing to stage 3 (clinical) diabetes and require accurate monitoring. Our aim was to establish continuous glucose monitoring (CGM) metrics that could predict immine
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8f6ab1c82ed7adfe91351710fdf6dda6
https://doi.org/10.2337/dc21-0602
https://doi.org/10.2337/dc21-0602
Publikováno v:
PharmacoEconomics. 39:1101-1107
The pipeline for new treatments for Alzheimer's disease (AD) in the USA contains over 100 different agents, 80% of which can be categorized as disease-modifying therapies. The regulatory approval of the disease-modifying agent aducanumab has brought
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::de3d385bd58dcf625585bdc255fa683c
https://doi.org/10.1007/s40273-021-01079-6
https://doi.org/10.1007/s40273-021-01079-6
Autor:
MARK TRUSHEIM, STEFAN KOSTENSE, LAURIC A. FERRAT, R. BRETT MCQUEEN, ROBERT D. NEUSNER, RICHARD A. ORAM, MARIAN REWERS, JESSICA L. DUNNE
Publikováno v:
Diabetes. 71
T1D screening and monitoring studies suggest opportunities for scaling up to public health population-based programs. Genetic Risk Scores (GRS) for T1D are also demonstrating the ability to identify those at higher risk of progressing to T1D as well
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c9dc81ca620533cf19f97e8981455147
https://doi.org/10.2337/db22-37-or
https://doi.org/10.2337/db22-37-or
Autor:
Heather D. Anderson, R. Brett McQueen, Sue Kwon, Garth Wright, Brock Schroeder, Michael S. Sherman, Taryn A. G. Quinlan, Jane F. Barlow
Publikováno v:
PharmacoEconomics Open
Background Harvard Pilgrim Health Care expanded coverage for non-invasive prenatal testing (NIPT) to include all pregnant, single-gestation women aged
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::63bdc2de3e1f1298951a5b0880ac367e
https://doi.org/10.1007/s41669-021-00261-y
https://doi.org/10.1007/s41669-021-00261-y